Global Oncology Molecular Diagnostics Market to Reach $10.8 Billion by 2030
The global market for Oncology Molecular Diagnostics estimated at US$4.6 Billion in the year 2022, is projected to reach a revised size of US$10.8 Billion by 2030, growing at a CAGR of 11.1% over the analysis period 2022-2030. Breast Cancer, one of the segments analyzed in the report, is projected to record 9.1% CAGR and reach US$2.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Colorectal Cancer segment is readjusted to a revised 14.7% CAGR for the next 8-year period.The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 14.3% CAGR
The Oncology Molecular Diagnostics market in the U.S. is estimated at US$1.2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 14.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 9.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.6% CAGR.Select Competitors (Total 12 Featured) -
- Abbott Laboratories
- Bayer Healthcare AG
- Beckman Coulter, Inc.
- Becton, Dickinson and Company
- Cepheid, Inc.
- Danaher Corporation
- Hologic, Inc.
- Leica Biosystems Inc.
- Qiagen NV
- Roche Diagnostics (Schweiz) AG
- Siemens Healthineers
- Sysmex Corporation
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Oncology Molecular Diagnostics - Global Key Competitors Percentage Market Share in 2020 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2020 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 18: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 21: World 16-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 22: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 23: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 24: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 25: World Oncology Molecular Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 26: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 27: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: World 16-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 29: USA Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: USA Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: USA 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 32: USA Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: USA Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: USA 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- CANADA
- Table 35: Canada Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Canada Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: Canada 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 38: Canada Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Canada Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Canada 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- JAPAN
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 41: Japan Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Japan Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Japan 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 44: Japan Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Japan Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: Japan 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- CHINA
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 47: China Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: China Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: China 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 50: China Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: China Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: China 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- EUROPE
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 53: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 59: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Europe Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- FRANCE
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 62: France Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: France Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: France 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 65: France Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: France Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: France 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- GERMANY
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 68: Germany Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Germany Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: Germany 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 71: Germany Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Germany Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: Germany 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- ITALY
- Table 74: Italy Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Italy Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: Italy 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 77: Italy Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Italy Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: Italy 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 80: UK Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: UK Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: UK 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 83: UK Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: UK Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: UK 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- SPAIN
- Table 86: Spain Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Spain Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: Spain 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 89: Spain Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Spain Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Spain 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- RUSSIA
- Table 92: Russia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Russia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Russia 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 95: Russia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Russia Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Russia 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 98: Rest of Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Rest of Europe 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 101: Rest of Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 103: Rest of Europe 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 106: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
- Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 108: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 109: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2023 & 2030
- Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 111: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 112: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2023 & 2030
- AUSTRALIA
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
- INDIA
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
- SOUTH KOREA
- REST OF ASIA-PACIFIC
- LATIN AMERICA
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
- ARGENTINA
- BRAZIL
- MEXICO
- REST OF LATIN AMERICA
- MIDDLE EAST
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
- IRAN
- ISRAEL
- SAUDI ARABIA
- UNITED ARAB EMIRATES
- REST OF MIDDLE EAST
- AFRICA
- Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Bayer Healthcare AG
- Beckman Coulter, Inc.
- Becton, Dickinson and Company
- Cepheid, Inc.
- Danaher Corporation
- Hologic, Inc.
- Leica Biosystems Inc.
- Qiagen NV
- Roche Diagnostics (Schweiz) AG
- Siemens Healthineers
- Sysmex Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 158 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 4.6 Billion |
Forecasted Market Value ( USD | $ 10.8 Billion |
Compound Annual Growth Rate | 11.3% |
Regions Covered | Global |